194 related articles for article (PubMed ID: 29074254)
21. Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.
Lin SY; Chang CF; Coumar MS; Chen PY; Kuo FM; Chen CH; Li MC; Lin WH; Kuo PC; Wang SY; Li AS; Lin CY; Yang CM; Yeh TK; Song JS; Hsu JTA; Hsieh HP
Bioorg Chem; 2020 May; 98():103689. PubMed ID: 32171993
[TBL] [Abstract][Full Text] [Related]
22. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
25. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
Guan H; Du Y; Han W; Shen J; Li Q
Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities.
Liang JW; Li WQ; Nian QY; Xie SH; Yang L; Meng FH
Bioorg Chem; 2022 Feb; 119():105547. PubMed ID: 34906858
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
Lee J; Kim KH; Jeong S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
[TBL] [Abstract][Full Text] [Related]
28. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
29. Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.
Tadesse S; Yu M; Mekonnen LB; Lam F; Islam S; Tomusange K; Rahaman MH; Noll B; Basnet SK; Teo T; Albrecht H; Milne R; Wang S
J Med Chem; 2017 Mar; 60(5):1892-1915. PubMed ID: 28156111
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors.
Mou J; Qiu S; Chen D; Deng Y; Tekleab T
Chem Biol Drug Des; 2021 Oct; 98(4):639-654. PubMed ID: 34233076
[TBL] [Abstract][Full Text] [Related]
31. A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.
Tadesse S; Zhu G; Mekonnen LB; Lenjisa JL; Yu M; Brown MP; Wang S
Future Med Chem; 2017 Sep; 9(13):1495-1506. PubMed ID: 28795589
[TBL] [Abstract][Full Text] [Related]
32. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
33. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1H-pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors.
Ganga Reddy V; Srinivasa Reddy T; Lakshma Nayak V; Prasad B; Reddy AP; Ravikumar A; Taj S; Kamal A
Eur J Med Chem; 2016 Oct; 122():164-177. PubMed ID: 27344493
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
[TBL] [Abstract][Full Text] [Related]
36. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
37. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.
Pecoraro C; Parrino B; Cascioferro S; Puerta A; Avan A; Peters GJ; Diana P; Giovannetti E; Carbone D
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011251
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
39. Pulchranin A: First report of isolation from an endophytic fungus and its inhibitory activity on cyclin dependent kinases.
Moussa AY; Mostafa NM; Singab ANB
Nat Prod Res; 2020 Oct; 34(19):2715-2722. PubMed ID: 30887847
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
